Meta AnalysisID 5961
中成药治疗功能性消化不良的效果：系统评价与贝叶斯网状Meta分析方案
CRD42021283940
Many clinical studies have suggested that various Chinese patent medicine seem to be potential in treating FD. However, the efficacy of different Chinese patent medicine for functional dyspepsia is still debated.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5961
- Evidence Id
- 14519
- Core Evidence Id
- 14519
- Source Meta Analysis Id
- 5944
- Herb2 Meta Analysis Id
- HBMA005944
- Crd Id
- CRD42021283940
- Title
- Chinese patent medicine for functional dyspepsia effects: a protocol for systematic review and Bayesian network meta-analysis
- Review Question
- Many clinical studies have suggested that various Chinese patent medicine seem to be potential in treating FD. However, the efficacy of different Chinese patent medicine for functional dyspepsia is still debated.
- Study Type Included
- Only randomized controlled trials will be included, whether blind or not. The publication languages are limited to Chinese and English.
- Condition Being Studied
- Functional dyspepsia: Functional dyspepsia is one of the most common diseases in gastroenterology outpatient, and its morbidity can be as high as 10%-30%, which is a worldwide public health problem. Chinese patent medicine is a kind of traditional Chinese medicine that is approved by China FDA and appeared on the market.
- Participant
- Patients were diagnosed with functional dyspepsia. The diagnostic criteria include Rome II, Rome III, and Rome IV.
- Animal
- Human Disease Modelled
- Intervention
- 9 kinds of Chinese patent medicines: Zhizhu Kuanzhong capsule, Qi-zhi-wei-tong granule, Wei-chang-an pill, Biling Weitong Granules, Si-mo-tang oral liquid, Dalitong granule, Liuwei Anxiao capsule, Liuwei Nengxiao capsule, Huoxiang Zhengqi capsule/pill.
- Comparator Control
- The control group is treated with placebo or western medicine (Domperidone or trimebutin or itobili or moxabili or omeprazole).
- Main Outcome
- effective rate, cure rate, recurrence rate, and functional dyspepsia symptom score
- Outcome Measure
- Additional Outcome
- Adverse events
- Study Method
- Meta-analysis, Network meta-analysis, Systematic review
- Keyword
- Bayes Theorem; China; Dyspepsia; Humans; Meta-Analysis as Topic; Network Meta-Analysis; Nonprescription Drugs
- Contact
- jingjie wu [email protected]
- Organisational Affiliation
- Jinshan hospital of integrated traditional Chinese and western medicine
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-10-09
- Registration Date
- 2021-11-09
- Anticipated Start Date
- 2021-10-01
- Anticipated Completion Date
- 2022-03-01
- Title Cn
- 中成药治疗功能性消化不良的效果：系统评价与贝叶斯网状Meta分析方案
- Title En
- Chinese patent medicine for functional dyspepsia effects: a protocol for systematic review and Bayesian network meta-analysis
- Bilingual Status
- complete